medication-upadacitinib-standard-dose-daily-protocol

Outcomes

01
mood-anxiety-hads-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
02
mood-depression-hads-scale-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
03
qol-dlqi-total-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
04
qol-patient-global-impression-of-change-pgii-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
05
qol-pgii-severity-change-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
06
qol-pgii-treatment-change-score-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
07
skin-atopic-dermatitis-adis-emotional-state-subscore-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
08
skin-atopic-dermatitis-scorad-total-score-clinician-assessed
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
09
skin-atopic-dermatitis-severity-score-adss-total-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
10
skin-pain-severity-nrs-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
11
skin-pruritus-poems-total-score-clinician-assessed
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
12
skin-pruritus-worst-nrs-0-to-10-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2
13
sleep-quality-overall-rating-self-reported
1 evidence row
- silverberg_2024_rct_early-and-sustained-improvements-in-symptoms-and-quality-of-life-with-upadacitinib-in-adults-and-adolescents-with-moderate-to-severe-atopic-dermatitis-52-week-results-from-two-phase-iii-randomized-clinical-trials-measure-up-1-and-measure-up-2

medication-upadacitinib-standard-dose-daily-protocol

Outcomes

mood-anxiety-hads-subscore-self-reported

mood-depression-hads-scale-subscore-self-reported

qol-dlqi-total-score-self-reported

qol-patient-global-impression-of-change-pgii-score-self-reported

qol-pgii-severity-change-score-self-reported

qol-pgii-treatment-change-score-self-reported

skin-atopic-dermatitis-adis-emotional-state-subscore-self-reported

skin-atopic-dermatitis-scorad-total-score-clinician-assessed

skin-atopic-dermatitis-severity-score-adss-total-self-reported

skin-pain-severity-nrs-self-reported

skin-pruritus-poems-total-score-clinician-assessed

skin-pruritus-worst-nrs-0-to-10-self-reported

sleep-quality-overall-rating-self-reported